EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Clinical Significance of CRNDE Gene Methylation, Polymorphisms, and CRNDEP Micropeptide Expression in Ovarian Tumors

Laura Aleksandra Szafron iD, Roksana Iwanicka-Nowicka iD, Agnieszka Podgorska, Arkadiusz M Bonna iD, Piotr Sobiczewski, Jolanta Kupryjanczyk, Lukasz Michal Szafron iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25147531 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Laura Aleksandra Szafron und 6 weiteren Autor:innen. Beteiligte Einrichtung: Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. Hauptthemen laut MEDLINE: Ovarian Neoplasms, RNA, Long Noncoding, DNA Methylation, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Center, National Science Centre in Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CRNDE is an oncogene expressed as a long non-coding RNA. However, our team previously reported that the CRNDE gene also encodes a micropeptide, CRNDEP. The amino acid sequence of CRNDEP has recently been revealed by other researchers, too. This study aimed to investigate genetic alterations within the CRNDEP-coding region of the CRNDE gene, methylation profiling of this gene, and CRNDEP expression analysis. All investigations were performed on clinical material from patients with ovarian tumors of diverse aggressiveness. We found that CRNDEP levels were significantly elevated in highly aggressive tumors compared to benign neoplasms. Consistently, a high level of this micropeptide was a negative, independent, prognostic, and predictive factor in high-grade ovarian cancer (hgOvCa) patients. The cancer-promoting role of CRNDE(P), shown in our recent study, was also supported by genetic and epigenetic results obtained herein, revealing no CRNDEP-disrupting mutations in any clinical sample. Moreover, in borderline ovarian tumors (BOTS), but not in ovarian cancers, the presence of a single nucleotide polymorphism in CRNDE, rs115515594, significantly increased the risk of recurrence. Consistently, in BOTS only, the same genetic variant was highly overrepresented compared to healthy individuals. We also discovered that hypomethylation of CRNDE is associated with increased aggressiveness of ovarian tumors. Accordingly, hypomethylation of this gene’s promoter/first exon correlated with hgOvCa resistance to chemotherapy, but only in specimens with accumulation of the TP53 tumor suppressor protein. Taken together, these results contribute to a better understanding of the role of CRNDE(P) in tumorigenesis and potentially may lead to improvements in screening, diagnosis, and treatment of ovarian neoplasms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsRNA, Long NoncodingDNA MethylationPolymorphism, Single NucleotideGene Expression Regulation, NeoplasticHumansFemaleMiddle AgedPrognosisAdultAgedPromoter Regions, GeneticBiomarkers, TumorClinical Relevance

Stichwörter der Autor:innen

CRNDECRNDEPDNA methylationDNA sequence variantIHCTP53lncRNAmicropeptideovarian cancer

Substanzen

RNA, Long NoncodingCRNDE RNA, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
  • Laboratory of Systems Biology, Faculty of Biology, University of Warsaw, 02-106 Warsaw, Poland.
  • Laboratory for Microarray Analysis, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland.
  • Cancer Molecular and Genetic Diagnostics Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
  • Triple Helical Peptides Ltd., Cambridge CB22 5DU, UK.
  • Department of Gynecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.

ORCID-Profile: Laura Aleksandra Szafron, Roksana Iwanicka-Nowicka, Arkadiusz M Bonna, Lukasz Michal Szafron

Förderung

  • National Science Center
  • National Science Centre in Poland

Zitieren

APA

Szafron, L. A., Iwanicka-Nowicka, R., Podgorska, A., Bonna, A. M., Sobiczewski, P., Kupryjanczyk, J., & Szafron, L. M. (2024). The Clinical Significance of CRNDE Gene Methylation, Polymorphisms, and CRNDEP Micropeptide Expression in Ovarian Tumors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147531

Vancouver

Szafron LA, Iwanicka-Nowicka R, Podgorska A, Bonna AM, Sobiczewski P, Kupryjanczyk J, et al. The Clinical Significance of CRNDE Gene Methylation, Polymorphisms, and CRNDEP Micropeptide Expression in Ovarian Tumors. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147531

BibTeX
@article{Szafron2024,
  author = {Szafron, Laura Aleksandra and Iwanicka-Nowicka, Roksana and Podgorska, Agnieszka and Bonna, Arkadiusz M and Sobiczewski, Piotr and Kupryjanczyk, Jolanta and Szafron, Lukasz Michal},
  title = {The Clinical Significance of CRNDE Gene Methylation, Polymorphisms, and CRNDEP Micropeptide Expression in Ovarian Tumors},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25147531}
}
Kostenlos starten →